New York, NY—November 21, 2019. Glycotest, Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis–cirrhosis, announced today that the Company has received the second $3 million tranche of the $10 million Series A funding round from Shanghai Fosun Pharmaceutical Co., Ltd. (“Fosun Pharma”). The focus of this [...]
New York, NY—February 14, 2019 Glycotest, Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis–cirrhosis, announced today that the Company has received the first $3 million tranche of the $10 million Series A funding round from Shanghai Fosun Pharmaceutical Co., Ltd. (“Fosun Pharma”). click to view the [...]
New York, NY—October 22, 2018. Glycotest Inc., Inc., a diagnostics company commercializing new and unique blood tests for life threatening liver cancers and fibrosis–cirrhosis, announced today the close of a Series A funding round of $10 million from Shanghai Fosun Pharmaceutical Co., Ltd. (“Fosun Pharma”). The transaction includes an equity investment of an initial tranche [...]
New York, NY – 04 January 2018 – Glycotest Inc., announced today that it successfully completed a clinical evaluation of its HCC Panel in China. In a blinded evaluation of 149 HCC patient and control samples, the HCC Panel achieved an AUROC of 0.97. Glycotest is a private liver disease diagnostics company commercializing new and [...]
New York, NY— October 05, 2017—Glycotest, Inc. announced today that a Japanese patent protecting fucosylated kininogen—a key biomarker in the Company’s lead HCC Panel test for earlystage liver cancer—has been granted. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to [...]
New York, NY—July 07, 2017—Glycotest, Inc. announced today that a European patent has been granted and additional United States and Australian patents have been allowed. Together these patents will extend protection of the Company’s core technology for early detection of life threatening liver disease. Glycotest is a private liver disease diagnostics company commercializing new and [...]